Multi-chip Meta-analysis of Parkinson's Disease for Clinical Validation of Small Samples of Key Genes in Disease

NCT03848455 | Completed Results DMC

• 1 other identifier: 2018-SJNK-008-1
• Study Type: observational
• Target: 238
• Locations: 1 country
• Sites: 1

Brief Summary

The research team used meta-analytical statistical methods to integrate the results of different research groups on Parkinson's disease, using meta-analysis to find key genes related to the pathogenesis and development of Parkinson's disease, and to make small clinical results. The verification of the sample, the internal mechanism of the pathogenesis of Parkinson's disease and provide guidance and reference for subsequent experimental research.

Conditions

Parkinson's Disease

Keywords

Parkinson's disease; synaptic correlation function; key gene

Outcome Measures

Primary Outcomes (3)

• Parkinson's Key Gene

  The blood of patients were taken for genetic testing and relative expression levels of the genes(These genes expression relative to a house keeping gene:GAPDH) for PPP2CA, PPP3CB, SYNJ1, NSF were extracted.The method we used is RT-PCR.

  3 days

• Unified Parkinson's Disease Rating Scale 3.0（UPDRS 3.0）

  The total score ranges from 0 to 199( minimum score is 0 and maximum scores is 199), in which a lower score denotes a better perception of the patient's. Scoring the mental, behavioral and emotional, daily living activities, exercise tests, and drug treatment complications associated with UPDRS3.0 in patients with Parkinson's disease;each item 0-4 points, total score 199 points, 0-50 points: limb and body mild dysfunction, posture response normal;51-100 points: mild postural reaction disorder, self-care in daily life, loss of labor force;101-199: obvious postural reaction disorder, loss of daily life and labor force, may need help to get up and confined to wheelchair life;The more severe the symptoms of Parkinson's disease, the higher the score.

  2 days

• Non-motor Symptom Scale (NMSS)

  Scoring based on the patient's own situation in the last month Severity: 1 = mild; 2 = moderate; 3 = severe Frequency: 1 = very little (less than once a week); 2 = often (1 time a week); 3 = frequent (a few times a week); 4 = very frequent (every day or persist)

  2 days

Study Arms (2)

Parkinson's disease group

1. Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria; 2. Newly diagnosed primary PD patients, diagnosed within 3-6 months; 3. informed consent to the study; 4. age \> 18 older.

Diagnostic Test: genetic diagnosis

Non-parkinson group

Non-parkinson group inclusion criteria: age, gender-matched PD group, non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history; informed consent to the study; age \> 18 older.

Diagnostic Test: genetic diagnosis

Interventions

genetic diagnosis DIAGNOSTIC_TEST

The venous blood of the two groups of patients was taken for genetic testing, and the expression levels of PPP2CA, PPP3CB, SYNJ1, NSF and CYCS were extracted by pre-processing the genetic data of PD and non-PD patients.

Non-parkinson group; Parkinson's disease group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

From March 25, 2019 to April 25, 2019, patients with Parkinson's disease who were admitted to the Department of Neurology, Zhujiang Hospital, and healthy volunteers who recruited from population of community and students of the Southern Medical University.

You may qualify if:

• PD group：
• Patients who meet the 2016 China Parkinson's diagnostic criteria and the 2015 International Parkinson's and Movement Disorders Association (MDS) Parkinson's disease diagnostic criteria
• Newly diagnosed primary PD patients, diagnosed within 3-6 months
• Informed consent to the study
• Age \> 18 older
• Non-PD group:
• Age, gender-matched PD group
• Non-PD, non-PDS, non-neurological degenerative disease, patients without inflammatory disease and related family history
• Informed consent to the study
• Age \> 18 older

You may not qualify if:

• Severe craniocerebral trauma patients
• Disturbance of consciousness
• Severe organic diseases, cerebral hemorrhage, cerebral thrombosis, severe coronary heart disease and lung disease, severe liver and kidney dysfunction, severe diabetes, severe hearing And visual impairment
• History of severe brain tumors, encephalitis or brain surgery

Sponsors & Collaborators

• Zhujiang Hospital: lead

Study Sites (1)

Zhujiang Hospiatal

Guangzhou, Guangdong, 510000, China

Location

Related Publications (6)

• Li X, Zhang Y, Wang Y, Xu J, Xin P, Meng Y, Wang Q, Kuang H. The Mechanisms of Traditional Chinese Medicine Underlying the Prevention and Treatment of Parkinson's Disease. Front Pharmacol. 2017 Sep 19;8:634. doi: 10.3389/fphar.2017.00634. eCollection 2017.

  PMID: 28970800 BACKGROUND

• Lee Y, Kim MS, Lee J. Neuroprotective strategies to prevent and treat Parkinson's disease based on its pathophysiological mechanism. Arch Pharm Res. 2017 Oct;40(10):1117-1128. doi: 10.1007/s12272-017-0960-8. Epub 2017 Sep 26.

  PMID: 28952032 BACKGROUND

• Lotankar S, Prabhavalkar KS, Bhatt LK. Biomarkers for Parkinson's Disease: Recent Advancement. Neurosci Bull. 2017 Oct;33(5):585-597. doi: 10.1007/s12264-017-0183-5. Epub 2017 Sep 21.

  PMID: 28936761 BACKGROUND

• Walsh CJ, Hu P, Batt J, Santos CC. Microarray Meta-Analysis and Cross-Platform Normalization: Integrative Genomics for Robust Biomarker Discovery. Microarrays (Basel). 2015 Aug 21;4(3):389-406. doi: 10.3390/microarrays4030389.

  PMID: 27600230 BACKGROUND

• Tseng GC, Ghosh D, Feingold E. Comprehensive literature review and statistical considerations for microarray meta-analysis. Nucleic Acids Res. 2012 May;40(9):3785-99. doi: 10.1093/nar/gkr1265. Epub 2012 Jan 19.

  PMID: 22262733 BACKGROUND

• Wang X, Kang DD, Shen K, Song C, Lu S, Chang LC, Liao SG, Huo Z, Tang S, Ding Y, Kaminski N, Sibille E, Lin Y, Li J, Tseng GC. An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection. Bioinformatics. 2012 Oct 1;28(19):2534-6. doi: 10.1093/bioinformatics/bts485. Epub 2012 Aug 3.

  PMID: 22863766 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

After admission, 2 tubes of venous blood (8ml) were extracted from PD group and control group respectively for genetic testing

MeSH Terms

Conditions

Parkinson Disease

Interventions

Preimplantation Diagnosis

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Intervention Hierarchy (Ancestors)

Diagnostic Techniques, Obstetrical and Gynecological; Diagnostic Techniques and Procedures; Diagnosis

Results Point of Contact

• Title: Xiaoya Gao
• Organization: Zhujiang Hospital of Southern Medical University

4356975@qq.com

18680282869

Study Officials

• Xiaoya Gao, doctor

  Southern Medical University, China

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Chief Physician

Study Record Dates

• First Submitted: February 19, 2019
• First Posted: February 20, 2019
• Study Start: February 25, 2019
• Primary Completion: February 20, 2021
• Study Completion: February 20, 2021
• Last Updated: July 28, 2023
• Results First Posted: January 18, 2020

Record last verified: 2023-07

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)